Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jan 21;7(1):2060. doi: 10.1038/cddis.2015.391

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 Macmillan Publishers Limited

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Myricetin and spinacine (5) can re-sensitize HPV⁺, but not HPV⁻, head and neck cancer cell lines to treatment with TRAIL. (a) Both HPV⁻ and HPV⁺ HN cancer cell lines display resistance to TRAIL treatment. (b) HPV⁻ (UMSCC 29 and SCC 84) and (c) HPV⁺ (UMSCC 47, UPCI-SCC90-UP-Clone 35, and UM-SCC47-TC-Clone 3) head and neck cancer cell lines (2 × 10⁴ cells per well) were seeded into 96-well plates and allowed to incubate overnight, and then cells were pretreated with myricetin (0–200 μM) or spinacine (0–100 μM) for 4 h. In all, 50 μM of TRAIL along with cycloheximide (5 μg/ml) was added, and cells were allowed to incubate overnight. Cell viability was measured by the MTT assay, and the viability of cells untreated with small molecules was set at 100%. Experiments were performed in triplicate, and error bars indicate the S.D.

Myricetin and spinacine (5) can re-sensitize HPV⁺, but not HPV⁻, head and neck cancer cell lines to treatment with TRAIL. (a) Both HPV⁻ and HPV⁺ HN cancer cell lines display resistance to TRAIL treatment. (b) HPV⁻ (UMSCC 29 and SCC 84) and (c) HPV⁺ (UMSCC 47, UPCI-SCC90-UP-Clone 35, and UM-SCC47-TC-Clone 3) head and neck cancer cell lines (2 × 10⁴ cells per well) were seeded into 96-well plates and allowed to incubate overnight, and then cells were pretreated with myricetin (0–200 μM) or spinacine (0–100 μM) for 4 h. In all, 50 μM of TRAIL along with cycloheximide (5 μg/ml) was added, and cells were allowed to incubate overnight. Cell viability was measured by the MTT assay, and the viability of cells untreated with small molecules was set at 100%. Experiments were performed in triplicate, and error bars indicate the S.D.